These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 39273024)

  • 1. A Non-Canonical p75HER2 Signaling Pathway Underlying Trastuzumab Action and Resistance in Breast Cancer.
    Nami B; Wang Z
    Cells; 2024 Aug; 13(17):. PubMed ID: 39273024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β2-AR activation promotes cleavage and nuclear translocation of Her2 and metastatic potential of cancer cells.
    Liu D; Zha L; Liu Y; Zhao X; Xu X; Liu S; Ma W; Zheng J; Shi M
    Cancer Sci; 2020 Dec; 111(12):4417-4428. PubMed ID: 33016509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.
    Feldinger K; Generali D; Kramer-Marek G; Gijsen M; Ng TB; Wong JH; Strina C; Cappelletti M; Andreis D; Li JL; Bridges E; Turley H; Leek R; Roxanis I; Capala J; Murphy G; Harris AL; Kong A
    Oncotarget; 2014 Aug; 5(16):6633-46. PubMed ID: 24952873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3.
    Ebbing EA; Medema JP; Damhofer H; Meijer SL; Krishnadath KK; van Berge Henegouwen MI; Bijlsma MF; van Laarhoven HW
    Oncotarget; 2016 Mar; 7(9):10243-54. PubMed ID: 26863569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of DPAGT1 suppresses HER2 shedding and trastuzumab resistance in human breast cancer.
    Yang M; Li Y; Kong L; Huang S; He L; Liu P; Mo S; Lu X; Lin X; Xiao Y; Shi D; Huang X; Chen B; Chen X; Ouyang Y; Li J; Lin C; Song L
    J Clin Invest; 2023 Jul; 133(14):. PubMed ID: 37463446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.
    Yang L; Bhattacharya A; Peterson D; Li Y; Liu X; Marangoni E; Robila V; Zhang Y
    Drug Resist Updat; 2024 May; 74():101078. PubMed ID: 38503142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
    Liu PC; Liu X; Li Y; Covington M; Wynn R; Huber R; Hillman M; Yang G; Ellis D; Marando C; Katiyar K; Bradley J; Abremski K; Stow M; Rupar M; Zhuo J; Li YL; Lin Q; Burns D; Xu M; Zhang C; Qian DQ; He C; Sharief V; Weng L; Agrios C; Shi E; Metcalf B; Newton R; Friedman S; Yao W; Scherle P; Hollis G; Burn TC
    Cancer Biol Ther; 2006 Jun; 5(6):657-64. PubMed ID: 16627989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
    Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
    Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteolytic cleavage of amyloid precursor protein by ADAM10 mediates proliferation and migration in breast cancer.
    Tsang JYS; Lee MA; Chan TH; Li J; Ni YB; Shao Y; Chan SK; Cheungc SY; Lau KF; Tse GMK
    EBioMedicine; 2018 Dec; 38():89-99. PubMed ID: 30470613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase.
    Tousseyn T; Thathiah A; Jorissen E; Raemaekers T; Konietzko U; Reiss K; Maes E; Snellinx A; Serneels L; Nyabi O; Annaert W; Saftig P; Hartmann D; De Strooper B
    J Biol Chem; 2009 Apr; 284(17):11738-47. PubMed ID: 19213735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer.
    Jiang L; Ren L; Chen H; Pan J; Zhang Z; Kuang X; Chen X; Bao W; Lin C; Zhou Z; Huang D; Yang J; Huang H; Wang L; Hou N; Song L
    Cell Death Dis; 2020 Jul; 11(7):547. PubMed ID: 32683421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting ITGβ3 to Overcome Trastuzumab Resistance through Epithelial-Mesenchymal Transition Regulation in HER2-Positive Breast Cancer.
    Boz Er AB; Er I
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.
    Lee JY; Joo HS; Choi HJ; Jin S; Kim HY; Jeong GY; An HW; Park MK; Lee SE; Kim WS; Son T; Min KW; Oh YH; Kong G
    J Natl Cancer Inst; 2019 Jun; 111(6):609-619. PubMed ID: 30265336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
    Wu D; Jia HY; Wei N; Li SJ
    Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
    Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
    Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer.
    Park M; Jung E; Park JM; Park S; Ko D; Seo J; Kim S; Nam KD; Kang YK; Farrand L; Hoang VH; Nguyen CT; La MT; Nam G; Park HJ; Ann J; Lee J; Kim YJ; Kim JY; Seo JH
    Theranostics; 2024; 14(6):2442-2463. PubMed ID: 38646654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.